Markus Axelsson
Overview
Explore the profile of Markus Axelsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindberg S, Sandgren S, Axelsson M, Rosenstein I, Lycke J, Novakova L
Mult Scler
. 2025 Feb;
:13524585251318516.
PMID: 39963891
Introduction: Reduced quality of life (QoL) is an early feature of multiple sclerosis (MS). The effect of progression independent of relapse activity (PIRA) on QoL is poorly investigated. Objective: To...
2.
Rosenstein I, Novakova L, Kvartsberg H, Nordin A, Rasch S, Rembeza E, et al.
J Neuroinflammation
. 2024 Dec;
21(1):320.
PMID: 39673059
Background: The Gas6/TAM (Tyro3, Axl, and Mer) receptor system has been implicated in demyelination and delayed remyelination in experimental animal models, but data in humans are scarce. We aimed to...
3.
Sandgren S, Novakova L, Nordin A, Sabir H, Axelsson M, Malmestrom C, et al.
Mult Scler Relat Disord
. 2024 Sep;
91:105894.
PMID: 39293124
Background: Relapsing-remitting multiple sclerosis (RRMS) is an inflammatory and neurodegenerative disease. After two or more short courses of alemtuzumab (ALZ), an immune reconstitution is achieved, which long-term results in reduced...
4.
Hafsteinsdottir B, Farman H, Lagerstrom N, Zetterberg H, Andersen O, Novakova L, et al.
J Neurol
. 2024 Sep;
271(11):7282-7293.
PMID: 39249104
Background: Elevated neurofilament light chain (NfL) levels are associated with worse prognosis in Guillain-Barré syndrome (GBS). Our objectives were to determine the utility of serum NfL (sNfL), cerebrospinal fluid (CSF)/serum...
5.
Pettersson M, Ericson Jogsten I, van Hees P, Karlsson P, Axelsson M, Yeung L
Chemosphere
. 2024 Aug;
364:143031.
PMID: 39117088
Per- and polyfluoroalkyl substances (PFAS) have been used for decades in a broad range of consumer products and industrial applications. A variety of waste and products containing PFAS inevitably end...
6.
Corderfeldt Keiller A, Axelsson M, Bragadottir G, Lannemyr L, Wijk J, Blennow K, et al.
J Cardiothorac Vasc Anesth
. 2024 Jul;
38(10):2204-2212.
PMID: 39069384
Objectives: To compare brain injury biomarker release levels between two different cardiopulmonary bypass (CPB) flow rates in elective cardiac surgery and to explore differences in postoperative delirium between groups and...
7.
Fernstrom E, Jarfelt M, Blomstrand M, Lannering B, Axelsson M, Wasling P, et al.
Ann Clin Transl Neurol
. 2024 Jul;
11(9):2382-2391.
PMID: 39030984
Objective: Treatment of pediatric brain tumors is associated with potential long-term cognitive sequelae. Patients treated with craniospinal irradiation for posterior fossa tumors are at high risk. New biomarkers that could...
8.
Rosen C, Mitre B, Nellgard B, Axelsson M, Constantinescu R, Andersen P, et al.
J Neurol Sci
. 2024 Jul;
463:123112.
PMID: 38972199
Amyotrophic lateral sclerosis (ALS) is a neurological disease without effective treatment. No pathognomonic test can diagnose ALS in sporadic cases. Routine investigation in suspected cases includes neurological examination, imaging of...
9.
Rosenstein I, Nordin A, Sabir H, Malmestrom C, Blennow K, Axelsson M, et al.
J Neurol
. 2024 Apr;
271(7):4412-4422.
PMID: 38668889
Objective: Insidious disability worsening is a common feature in relapsing-remitting multiple sclerosis (RRMS). Many patients experience progression independent of relapse activity (PIRA) despite being treated with high efficacy disease-modifying therapies....
10.
Novakova L, Hedstrom A, Axelsson M, Brandt A, Alfredsson L, Olsson T, et al.
Brain Behav
. 2024 Mar;
14(3):e3459.
PMID: 38451005
Background: A significant proportion of individuals with suspicious onset of multiple sclerosis (MS) does not fulfill the diagnostic criteria. Although some receive other diagnoses, many remain undiagnosed and lack healthcare...